These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-001212-44 Letrozole adjuvant therapy duration (LEAD)study: standard versus long treatment. A phase III study in postmenopausal women with early breast cancer Terapia ormonale adiuvante con letrozolo: terapia... not-yet-due
Ongoing 2005-001213-18 Letrozole adjuvant therapy after tamoxifen. Study of gene CYP19 correlation with letrozole efficacy in postmenopausal early breast cancer patients Terapia adiuvante con Letrozolo dopo Tamoxifene. S... not-yet-due
Completed, but no date Terminated 2005-005548-21 Phase I-II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Erlotinib (EGFR TKI) plus Oxaliplatin and Capecitabine (XELOX) in Patients with Metastatic Colorectal Cancer: XELOX-TARAV study bad-data
Completed, but no date 2007-005977-67 SUNITINIB EITHER BEFORE OR AFTER CYTOREDUCTIVE NEPHRECTOMY A PHASE II TRIAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA bad-data
Ongoing 2007-006031-30 A Randomized Trial with factorial Design comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in metastatic breast cancer progressing after Aromatase Inhibitor therapy not-yet-due
Ongoing 2008-000486-29 A feasibility study of dose-dense FEC wiith G-CSF support followed by dose-dense Ixabepilone wiith G-CSF support as neoadjuvant chemotherapy in ER- negative breast cancer not-yet-due
Ongoing 2008-006798-33 Medical optimization of TORisel (MoTOR): MULTICENTER, PHASE II EVALUATION OF TORISEL AS II-LINE TREATMENT FOR METASTATIC RCC PATIENTS PROGRESSING AFTER CYTOKINE THERAPY, TYROSINE KINASE, OR ANGIOGENES... not-yet-due
Ongoing 2013-003194-10 A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Bre... not-yet-due
Ongoing 2013-005044-29 A randomised, multicentre, open-label Phase II trial investigating activity of chemotherapy and lapatinib and Trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) refractory to an... not-yet-due
Ongoing 2014-003798-41 Randomized phase III study of fulvestrant as maintenance therapy after first-line chemotherapy in HER2 negative postmenopausal metastatic breast cancer patients Studio randomizzato di fase III di F... not-yet-due
Ongoing 2014-004035-38 Fulvestrant ed EVerolimus più EXemestane nel carcinoma mammario metastatico” “Fulvestrant followed by everolimus plus exemestane vs examestane and everolimus followed by fulvestrant in postmenopausal ... not-yet-due
Exempt Terminated 2015-000194-12 Isoquercetin as an adjunct therapy in patients with kidney cancer receiving first-line sunitinib: a phase I/II trial Isoquercetina come terapia di supporto nei pazienti affetti da tumore del rene i... not-yet-due
Ongoing 2015-003316-20 One day antiemetic prophylaxis of NEPA (netupitant plus palonosetron) and dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients receiving a combination che... not-yet-due
Completed, but no date, and reported results 2015-005704-29 A standard regimen of dexamethasone in comparison to two dex-sparing regimens in addition to NEPA in preventing CINV in na¿ve NSCLC patients to be treated with cisplatin based chemotherapy: a three-ar... bad-data
Completed, but no date Terminated 2016-005251-25 CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, pros... bad-data
Ongoing 2017-004652-35 Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Breast Cancer (MBC) patients: a randomized phase II study – ERICA trial ERIbulina in seconda linea ... not-yet-due
Ongoing 2018-000670-29 Avelumab as single agent in metastatic or locally advanced urothelial cancer in patients unfit for cisplatin. The ARIES Study Avelumab in monoterapia nel carcinoma uroteliale metastatico o localmen... not-yet-due
Not reported Terminated 2018-003027-11 A prospective, multi-center, open-label, single-arm, two- step phase II study of DURvalumab (MEDI4736) in patients WIth poor performance status as first-liNe treatment for advanced urothelial cancer: ... 2022-06-28 due-trials
Ongoing 2019-000221-45 Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a C... not-yet-due
Ongoing 2019-001388-55 A Phase II Trial of atezolizumab plus carboplatin plus paclitaxel as first-line therapy in metastatic Triple-negative PD-L1 positive breast cancer patients Studio Clinico di fase II con atezolizuma... not-yet-due
Ongoing 2019-004098-23 Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study). Studio di fase II sull’uso in prima linea di avelumab in ... not-yet-due
Ongoing 2022-001077-30 Efficacy of PErioperative PEmbrolizumab treatment in patients with resectable metastases from kidney cancer. The PE-PE study. Efficacia del trattamento PErioperatorio con PEmbrolizumab nei pazienti... not-yet-due
Ongoing 2022-001150-35 Phase II study of axitinib intensification plus nivolumab compared to nivolumab alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response (AxIn study). ... not-yet-due